Alexeynovikov / iStockphoto.com
20 November 2018Americas
10x Genomics sued over cell research tools
Genome sequencing company 10x Genomics has been accused of infringing 11 patents covering cell research and analysis tools.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
15 February 2018 The US International Trade Commission will be launching a patent infringement investigation into microfluidic systems, following a complaint from 10x Genomics.
Big Pharma
23 October 2019 US biotechnology company 10x Genomics is to pay its competitor, Becton Dickinson, $25 million as part of a deal to end worldwide patent infringement litigation between the companies.
Editor's picks
Editor's picks
Americas
15 February 2018 The US International Trade Commission will be launching a patent infringement investigation into microfluidic systems, following a complaint from 10x Genomics.
Big Pharma
23 October 2019 US biotechnology company 10x Genomics is to pay its competitor, Becton Dickinson, $25 million as part of a deal to end worldwide patent infringement litigation between the companies.
Americas
15 February 2018 The US International Trade Commission will be launching a patent infringement investigation into microfluidic systems, following a complaint from 10x Genomics.
Big Pharma
23 October 2019 US biotechnology company 10x Genomics is to pay its competitor, Becton Dickinson, $25 million as part of a deal to end worldwide patent infringement litigation between the companies.